Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases

OBJECTIVE: To compare the efficacy and adverse effects of paclitaxel-etoposide-carboplatin/cisplatin (TEP/TCE) regimen with those of etoposide-carboplatin/cisplatin (EP/CE) regimen as first-line treatment for combined small-cell lung cancer (CSCLC). METHODS: A retrospective study was conducted on 62...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue-Ya, Zhou, Chan, Yang, Deng-Xia, Wang, Jing, Liu, Zhu-Jun, Wang, Xin-Yue, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493380/
https://www.ncbi.nlm.nih.gov/pubmed/26175927
http://dx.doi.org/10.7497/j.issn.2095-3941.2015.0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493380/
https://www.ncbi.nlm.nih.gov/pubmed/26175927
http://dx.doi.org/10.7497/j.issn.2095-3941.2015.0012

Ejemplares similares